Alkermes Inc. of Cambridge, Mass., on Tuesday said itcompleted its initial public offering of 1.75 million shares ofcommon stock (NASDAQ:ALKS) at $10 per share, raising $17.5million. Managing underwriters are Robertson, Stephens & Co.and J.P. Morgan Securities Inc. The company now has 7.3million shares outstanding.
Alkermes Inc. develops therapeutic and diagnostic products totreat central nervous system disorders.
(c) 1997 American Health Consultants. All rights reserved.